Overview of current drug delivery methods across the blood-brain barrier for the treatment of primary brain tumors. Haumann R, Carvalho Videira J, Kaspers GJL, van Vuurden DG, Hulleman E. (2020).. CNS Drugs, in press.

A high-throughput image-guided stereotactic neuronavigation and focused ultrasound system for blood-brain barrier opening in rodents. Haumann R, ‘t Hart E, Derieppe MPP, Besse HC, Kaspers GJL, Hoving E, van Vuurden DG, Hulleman E, Ries M. (2020). J Vis Exp (161).

Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells. Wiese M, Hamdan F, Kubiak K, Diederichs C, Gielen G, Nussbaumer G, Carcaboso A, Hulleman E, Johnsen S, Kramm C. (2020).. Cell Death Dis 11(8), 673.

Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma. Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, Breur M, Buil LCM, Lagerweij T, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero Carcaboso Á, Bugiani M, Phoenix TN, van Tellingen O, van Vuurden DG, Kaspers GJL, Hulleman E. (2020). Clin Cancer Res, 26(13), 3319-3332.

Development of transient radioresistance during fractionated irradiation in vitro. Van den Berg J, Castricum KCM, Meel MH, Goedegebuure RSA, Lagerwaard FJ, Slotman BJ, Hulleman E*, Thijssen VLJL. (2020). Radiother Oncol 148, 107-114.

Immunotherapy in pediatric brain tumors: considerations, challenges and future directions. Kruithof ES, van der Lugt J, Hulleman E. (2019). J Mol Clin Med 2(3), 79-91.

Patient-derived orthotopic xenograft models of pediatric brain tumors: in a mature phase or still in its infancy? Hermans E, Hulleman E. (2019). Front Oncol 9, 14-18.

Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. Metselaar DS, Meel MH, Benedict B, Waranecki P, Koster J, Kaspers GJL, Hulleman E. (2019). Ebiomedicine 50, 81-92.

Signaling pathways and mesenchymal transition in pediatric high-grade glioma. Meel MH, Schaper SA, Kaspers GJL, Hulleman E. (2018). Cell Mol Life Sci, 75, 871-887. PubMed PMID: 29164272


Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. Bugiani M, Veldhuijzen van Zanten SEM, Caretti V, Schellen P, Aronica E, Noske DP, Vandertop WP, Kaspers GJL, van Vuurden DG, Wesseling P, Hulleman E. (2017). Oncotarget 8, 60447-60452. PubMed PMID: 28947983

Preclinical evaluation of convection-enhanced delivery with liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Montero-Carcaboso A, Gaillard PJ, Vandertop WP, Wesseling P, Noske DP, Kaspers GJL, Hulleman E. (2017). J Neurosurg Pediatr 17, 1-13. PubMed PMID: 28291423

Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-Bevacizumab PET imaging in brain tumor models. Jansen MHA, Lagerweij T, Sewing ACP, Vugts DJ, van Vuurden DG, Molthoff CFM, Caretti V, Veringa SJE, Petersen N, Montero-Carcaboso A, Noske DP, Vandertop WP, Wesseling P, van Dongen GAMS, Kaspers GJL, Hulleman E. (2016). Mol Cancer Ther 15, 2166-2174. PubMed PMID: 27325687

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen s, Johung TB, Sun w, Kogiso M, Du Y, Qi L, Huang Y, Hutt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe E, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M. (2015) Nat Med 21, 555-559. PubMed PMID: 25939062